Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Allergan, Esprit, Indevus deal

AGN will acquire Esprit for $370 million in cash. Esprit markets Sanctura trospium to treat overactive bladder (OAB) and Estrasorb topical 17beta estradiol

Read the full 233 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE